Featured Reviews in Genetics or Biochemical Research for Antimicrobials

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Genetic and Biochemical Studies of Antibiotic Activity and Resistance".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 5281

Special Issue Editors


E-Mail Website
Guest Editor
Center for Peptide-Based Antibiotics, Department of Biology, University of Copenhagen, 2200 Copenhagen, Denmark
Interests: antibiotic resistance; functional genomics; clinical resistance

E-Mail Website
Co-Guest Editor
Department of Biology, University of Copenhagen, 2200 Copenhagen, Denmark
Interests: bacterial cell cycle; mechanism and regulation of chromosomal replication initiation; initiator proteins; DNA methylation; antibiotic inhibition of chromosome replication; designing whole cell screens for discovery of new antibiotics; antimicrobial peptides
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the golden era of antibiotic discovery (e.g. 1940s through the 1960s), effective antibiotics were frequently discovered and introduced to the market. Now antimicrobial resistance is one of the major challenges of the 21st century. One of the proposed solutions to circumvent this crisis is to bring novel antimicrobial compounds into clinical use.

This Special Issue of Antibiotics titled ‘Featured Reviews in Genetics or Biochemical Research for Antimicrobials’ deals with all aspects of antimicrobials, from their discovery to their structural and functional characterization on microbes, as well as their evaluation in clinical trials. Prospective contributors are encouraged to submit their best review articles in this important and relevant field of scientific research.

Dr. Jakob Frimodt-Møller
Prof. Dr. Anders Løbner-Olesen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbes
  • bacteria
  • bacterial resistance
  • clinical trials
  • antimicrobial peptides
  • antibacterial peptides
  • antibiotics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 4204 KiB  
Review
A Riboswitch-Driven Era of New Antibacterials
by Nikoleta Giarimoglou, Adamantia Kouvela, Alexandros Maniatis, Athanasios Papakyriakou, Jinwei Zhang, Vassiliki Stamatopoulou and Constantinos Stathopoulos
Antibiotics 2022, 11(9), 1243; https://doi.org/10.3390/antibiotics11091243 - 13 Sep 2022
Cited by 14 | Viewed by 4875
Abstract
Riboswitches are structured non-coding RNAs found in the 5′ UTR of important genes for bacterial metabolism, virulence and survival. Upon the binding of specific ligands that can vary from simple ions to complex molecules such as nucleotides and tRNAs, riboswitches change their local [...] Read more.
Riboswitches are structured non-coding RNAs found in the 5′ UTR of important genes for bacterial metabolism, virulence and survival. Upon the binding of specific ligands that can vary from simple ions to complex molecules such as nucleotides and tRNAs, riboswitches change their local and global mRNA conformations to affect downstream transcription or translation. Due to their dynamic nature and central regulatory role in bacterial metabolism, riboswitches have been exploited as novel RNA-based targets for the development of new generation antibacterials that can overcome drug-resistance problems. During recent years, several important riboswitch structures from many bacterial representatives, including several prominent human pathogens, have shown that riboswitches are ideal RNA targets for new compounds that can interfere with their structure and function, exhibiting much reduced resistance over time. Most interestingly, mainstream antibiotics that target the ribosome have been shown to effectively modulate the regulatory behavior and capacity of several riboswitches, both in vivo and in vitro, emphasizing the need for more in-depth studies and biological evaluation of new antibiotics. Herein, we summarize the currently known compounds that target several main riboswitches and discuss the role of mainstream antibiotics as modulators of T-box riboswitches, in the dawn of an era of novel inhibitors that target important bacterial regulatory RNAs. Full article
Show Figures

Figure 1

Back to TopTop